TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: GlobeNewswire
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2026 annual meeting in Chicago. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We are excited to present new data at AAN 2026 further supporting the differentiated profile of BRIUMVI for people living with relapsing multiple sclerosis. The results from the ENABLE and ENHANCE studies continue to build on our growing body of evidence demonstrating the real-world effectiveness, safety, and tolerability of BRIUMVI, and provide insights into optimized dosing approaches for IV BRIUMVI, respectively. We look forward to continuing to expand the clinical and real-world data supporting BRIUMVI as an important treatment option in adults with RMS.”TG PR
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook [Seeking Alpha]Seeking Alpha
- A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics concludes enrolment in Phase III Briumvi trial [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVIGlobeNewswire
TGTX
Earnings
- 2/26/26 - Miss
TGTX
Analyst Actions
- 2/2/26 - JP Morgan
TGTX
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form 8-K
- 2/27/26 - Form 10-K
- TGTX's page on the SEC website